Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Mayo Clinic
Study ID
NCT03821857
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
60 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • 18-F-Flortaucipir — DRUG
    Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology

Study Details

The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.

Key Dates

Start date
Jun 27, 2019
Status verified
Nov 2025
Primary completion
May 31, 2030
Completion
May 31, 2030

Study Design

Enrollment
614 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Women
    18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology

Primary Outcome Measure

18F-Flortaucipir PET imaging [ Time Frame: 1 day ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo ClinicJacksonvilleFlorida32224
Twilla Morrell, CRC
[email protected]
904-953-3420
Ercilia Moncayo, CRC
[email protected]
904-953-3308
Neill Graff-Radford, MD (PRINCIPAL_INVESTIGATOR)
Mayo ClinicRochesterMinnesota55905-

Find similar trials in Jacksonville, FL

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Mayo Clinic· Jacksonville, FLMayo Clinic· Rochester, MN

Related Studies